A few studies in humans have also proven that utilization of GLP-1R agonists can improve hepatic steatosis, particularly in type 2 diabetes patients with NAFLD (as reviewed in 11). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.